Rambam Health Care Campus

Trial registries list this institution under these names. Each row is one registry entry: its address and the trials registered under it.

• Rambam Health Care Campus

  Haifa, Northern District 3109601

  154 trials

• Rambam Health Care Campus (RHCC)

  Haifa, 3109601

  5 trials

• Rambam Health Care Campus (Site 0076)

  Haifa, 3109601

  3 trials

  • NCT06780098Substudy 01I: A Study of Investigational Agents in Participants With Previously Treated Stage IV Squamous Non-small Cell Lung Cancer (NSCLC) (MK-3475-01I/KEYMAKER-U01I)

    Contact: Study Coordinator

  • NCT06780085A Study of Investigational Agents in Participants With Previously Treated Stage IV Nonsquamous Non-small Cell Lung Cancer (NSCLC) (MK-3475-01H/KEYMAKER-U01)

  • NCT06731907A Study of Pembrolizumab With or Without Chemotherapy in Combination With Additional Treatments for Advanced Non-Small Cell Lung Cancer (NSCLC) (MK-3475-01G/KEYMAKER U01)

    Contact: Study Coordinator

• Rambam Health Care Campus, Oncology Institute

  Haifa, 3109601

  2 trials

  • NCT03443856Postoperative Immunotherapy vs Standard Chemotherapy for Gastric Cancer With High Risk for Recurrence

  • NCT03377491Effect of Tumor Treating Fields (TTFields, 150 kHz) as Front-Line Treatment of Locally-advanced Pancreatic Adenocarcinoma Concomitant With Gemcitabine and Nab-paclitaxel (PANOVA-3)

• Rambam Health Care Campus (Site 0802)

  Haifa, 3109601

  2 trials

  • NCT06925750A Clinical Study of Sotatercept (MK-7962) in People With Pulmonary Arterial Hypertension (MK-7962-031/LIGHTRAY EXTENSION)

  • NCT06664801A Clinical Study of Sotatercept (MK-7962) in People With Pulmonary Arterial Hypertension (PAH) (MK-7962-024)

• Rambam Health Care Campus (Site 1402)

  Haifa, 3109601

  2 trials

  • NCT07776691A Study of Raludotatug Deruxtecan With or Without Bevacizumab as First-Line Maintenance Treatment in Non-HRD-Positive Advanced Ovarian Cancer (MK-5909-006, (ENGOT-ov102/GOG-3141/ REJOICE-Ovarian 04)

    Contact: Study Coordinator

  • NCT06824467A Study to Evaluate the Efficacy and Safety of Sacituzumab Tirumotecan (MK-2870) Maintenance Treatment Versus Standard of Care in Participants With Platinum-sensitive Recurrent Ovarian Cancer (MK-2870-022/TroFuse-022/ENGOT-ov84/GOG-3103)

    Contact: Study Coordinator

• Rambam Health Care Campus (Site 1907)

  Haifa, 3109601

  2 trials

  • NCT07216703A Clinical Study of Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) as First-line Maintenance Treatment of Cervical Cancer (MK-2870-036/TroFuse-036/GOG-3123/ENGOT-cx22)

    Contact: Study Coordinator

  • NCT05008224Study of Safety and Efficacy of Pembrolizumab and Chemotherapy in Participants With Newly Diagnosed Classical Hodgkin Lymphoma (cHL) (MK-3475-C11/KEYNOTE-C11)

• Rambam Health Care Campus

  Bat Galim, 3109601

  1 trial

  • NCT04613596Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G12C Mutation KRYSTAL-7

    Contact: Kamel Mhameed, Site 007-266

• Rambam Health Care Campus

  Hafia, 3109601

  1 trial

  • NCT05911295Disitamab Vedotin With Pembrolizumab vs Chemotherapy in Previously Untreated Urothelial Cancer Expressing HER2

• Rambam Health Care Campus- Haifa /ID# 257769

  Haifa, 3109601

  1 trial

  • NCT06012240A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants With Severe Alopecia Areata

• Rambam Health Care Campus- Haifa /ID# 260421

  Haifa, 3525408

  1 trial

  • NCT06107426Real-World Study of ABBV-951 Subcutaneous Infusion to Assess Change in Disease Activity in Adult Participants With Parkinson's Disease

• Rambam Health Care Campus- Haifa /ID# 261770

  Haifa, 3109601

  1 trial

  • NCT06318273A Study to Assess Adverse Events, and How Intravenously (IV) Infused ABBV-969 Moves Through the Bodies of Adult Participants With Metastatic Castration-Resistant Prostate Cancer

• Rambam Health Care Campus- Haifa /ID# 262994

  Haifa, 3109601

  1 trial

  • NCT06468228A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa

• Rambam Health Care Campus- Haifa /ID# 267641

  Haifa, 3109601

  1 trial

  • NCT06548542Study of Targeted Therapies for the Treatment of Adult Participants With Moderate to Severe Crohn's Disease

• Rambam Health Care Campus- Haifa /ID# 267739

  Haifa, Haifa District 3109601

  1 trial

  • NCT06614192A Study Assessing Adverse Events and Disease Activity of Intravenously (IV) Infused Telisotuzumab Adizutecan in Adult Participants With c-Met Protein Above Cutoff Level Above Refractory Metastatic Colorectal Cancer

• Rambam Health Care Campus- Haifa /ID# 268006

  Haifa, 3109601

  1 trial

  • NCT06820463A Study to Evaluate the Adverse Events, and Efficacy of Intravenous (IV) of Telisotuzumab Adizutecan in Combination With IV Oxaliplatin, Fluorouracil, Folinic Acid/Leucovorin, Bevacizumab, Panitumumab in Adult Participants With Metastatic Colorectal Cancer

• Rambam Health Care Campus- Haifa /ID# 270078

  Haifa, 3109601

  1 trial

  • NCT06568939A Study to Assess Adverse Events and How Intravenously (IV) Infused Telisotuzumab Vedotin (ABBV-399) Moves Through the Body as a Monotherapy in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC)

• Rambam Health Care Campus- Haifa /ID# 271256

  Haifa, 3109601

  1 trial

  • NCT06953960A Study to Assess Adverse Events and Change in Disease Activity of Oral Surzetoclax Alone or in Combination With Subcutaneous and/or Oral Antimyeloma Agents in Adult Participants With Multiple Myeloma (MM)

• Rambam Health Care Campus- Haifa /ID# 271364

  Haifa, 3109601

  1 trial

  • NCT06892522A Study to Assess Change in Disease Activity and Adverse Events (AE)s in Adult Participants With Multiple Myeloma Receiving T Cell Engaging Bi/Tri-specific Antibodies Intravenously (IV)/Subcutaneously (SC) Alone or in Combinations

• Rambam Health Care Campus- Haifa /ID# 273347

  Haifa, 3109601

  1 trial

  • NCT06880744A Study to Assess the Change in Disease Activity in Adult Participants With Moderate to Severe Ulcerative Colitis Treated With Risankizumab Compared to Vedolizumab

• Rambam Health Care Campus- Haifa /ID# 274542

  Haifa, 3109601

  1 trial

  • NCT07005102A Study to Assess Adverse Events, Change in Disease Activity of Intravenous Telisotuzumab Adizutecan in Combination With Osimertinib as First-Line Treatment in Adult Participants With Locally Advanced Unresectable or Metastatic EGFR-Mutated Non-Squamous Non-Small Cell Lung Cancer

• Rambam Health Care Campus- Haifa /ID# 276004

  Haifa, 3109601

  1 trial

  • NCT07024784A Study to Assess Change in Disease Activity and Adverse Events in Adult Participants With Gynecologic Cancers Receiving Intravenous Infusion of IMGN151 as Monotherapy or in Combination With Other Therapies

• Rambam Health Care Campus- Haifa /ID# 276663

  Haifa, 3109601

  1 trial

  • NCT07155174A Study to Evaluate the Optimal Dose, Adverse Events and Change in Disease Activity of Intravenous ABBV-706 in Combination With Atezolizumab Versus Standard of Care as First-Line Treatment in Adult Participants With Previously Untreated Extensive Stage Small Cell Lung Cancer

• Rambam Health Care Campus- Haifa /ID# 276746

  Haifa, 3109601

  1 trial

  • NCT07155187A Study to Assess Adverse Events and Change in Disease Activity of Intravenous (IV) Telisotuzumab Adizutecan, Monotherapy or in Combination With Osimertinib, Compared to Standard of Care in Adult Participants With Locally Advanced or Metastatic EGFR-Mutated Non-Squamous Non-Small Cell Lung Cancer

• Rambam Health Care Campus- Haifa /ID# 276799

  Haifa, 3109601

  1 trial

  • NCT07241039A Study to Assess the Adverse Events, Change in Disease Activity, and How Oral ABBV-711 Tablets Move Through the Body as a Monotherapy and in Combination With Intravenously Infused Budigalimab (ABBV-181), in Adults With Advanced Squamous Tumors

• Rambam Health Care Campus- Haifa /ID# 278719

  Haifa, 3109601

  1 trial

  • NCT07581002A Study to Assess Adverse Events and Change in Disease Activity When Intravenous (IV) Pivekimab Sunirine is Given in Combination With Oral Venetoclax and IV or Subcutaneous Azacitidine in Adult Participants With Acute Myeloid Leukemia (AML)

• Rambam Health Care Campus - Hematology and Bone Marrow Transplantation Institute

  Haifa, 3109601

  1 trial

  • NCT02290951Study to Investigate the Safety and Tolerability of Odronextamab in Patients With CD20+ B-Cell Malignancies

• Rambam Health Care Campus /ID# 124916

  Haifa, 3109601

  1 trial

  • NCT02163694A Phase 3 Randomized, Placebo-controlled Trial of Carboplatin and Paclitaxel With or Without Veliparib (ABT-888) in HER2-negative Metastatic or Locally Advanced Unresectable BRCA-associated Breast Cancer

• Rambam Health Care Campus /ID# 129282

  Haifa, 3109601

  1 trial

  • NCT01848561A Long-Term Registry of Humira® (Adalimumab) in Patients With Moderately to Severely Active Ulcerative Colitis (UC)

• Rambam Health Care Campus /ID# 150416

  Haifa, 3109601

  1 trial

  • NCT03006068A Study to Evaluate the Long-Term Safety and Efficacy of Upadacitinib (ABT-494) in Participants With Ulcerative Colitis (UC)

• Rambam Health Care Campus /ID# 152050

  Haifa, 3109601

  1 trial

  • NCT02629159A Study Comparing Upadacitinib (ABT-494) to Placebo and to Adalimumab in Adults With Rheumatoid Arthritis Who Are on a Stable Dose of Methotrexate and Who Have an Inadequate Response to Methotrexate

• Rambam Health Care Campus /ID# 154174

  Haifa, 3109601

  1 trial

  • NCT02993523A Study of Venetoclax in Combination With Azacitidine Versus Azacitidine in Treatment Naïve Participants With Acute Myeloid Leukemia Who Are Ineligible for Standard Induction Therapy

• Rambam Health Care Campus /ID# 162061

  Haifa, 3109601

  1 trial

  • NCT02130362A Non-Interventional Clinical Study to Evaluate Long-Term Safety and Effectiveness of HUMIRA (Adalimumab) in Pediatric Patients With Moderately to Severely Active Crohn's Disease (CD)

• Rambam Health Care Campus /ID# 169678

  Haifa, H_efa 3109601

  1 trial

  • NCT03539744A Study Designed to Evaluate the Safety and Efficacy of Venetoclax Plus Dexamethasone (VenDex) Compared With Pomalidomide Plus Dexamethasone (PomDex) in Participants With t(11;14)-Positive Relapsed or Refractory Multiple Myeloma.

• Rambam Health Care Campus /ID# 171096

  Haifa, 3109601

  1 trial

  • NCT03398135A Study to Assess the Efficacy and Safety of Risankizumab in Participants With Ulcerative Colitis

• Rambam Health Care Campus /ID# 204866

  Haifa, 3109601

  1 trial

  • NCT03539536Study of Telisotuzumab Vedotin (ABBV-399) in Participants With Previously Treated c-Met+ Non-Small Cell Lung Cancer

• Rambam Health Care Campus /ID# 208169

  Haifa, 3109601

  1 trial

  • NCT03671148A Study Comparing Risankizumab to Placebo in Participants With Active Psoriatic Arthritis Including Those Who Have a History of Inadequate Response or Intolerance to Biologic Therapy(Ies)

• Rambam Health Care Campus /ID# 208170

  Haifa, 3109601

  1 trial

  • NCT03675308A Study Comparing Risankizumab to Placebo in Participants With Active Psoriatic Arthritis (PsA) Who Have a History of Inadequate Response to or Intolerance to at Least One Disease Modifying Anti-Rheumatic Drug (DMARD) Therapy

• Rambam Health Care Campus /ID# 210320

  Haifa, 3109601

  1 trial

  • NCT03659669A Study to Describe the Effectiveness and Safety of Venetoclax Treatment in Chronic Lymphocytic Leukemia (CLL) Patients in Routine Clinical Practice

• Rambam Health Care Campus /ID# 213355

  Haifa, 3109601

  1 trial

  • NCT03987958A Study to Describe the Safety and Effectiveness of Venetoclax in Acute Myeloid Leukemia (AML) Patients (REVIVE Study)

• Rambam Health Care Campus /ID# 217536

  Haifa, 3109601

  1 trial

  • NCT04189614An Efficacy and Safety Study of Cofetuzumab Pelidotin in Participants With PTK7-Expressing, Recurrent Non-Small Cell Lung Cancer

• Rambam Health Care Campus /ID# 219120

  Haifa, H_efa 3109601

  1 trial

  • NCT04472598Study of Oral Navitoclax Tablet In Combination With Oral Ruxolitinib Tablet When Compared With Oral Ruxolitinib Tablet To Assess Change In Spleen Volume In Adult Participants With Myelofibrosis

• Rambam Health Care Campus /ID# 219121

  Haifa, H_efa 3109601

  1 trial

  • NCT04468984Study of Oral Navitoclax Tablet in Combination With Oral Ruxolitinib Tablet Versus Best Available Therapy to Assess Change in Spleen Volume in Adult Participants With Relapsed/Refractory Myelofibrosis

• Rambam Health Care Campus /ID# 221083

  Haifa, 3109601

  1 trial

  • NCT04401748Study Of Venetoclax Tablet With Intravenous or Subcutaneous Azacitidine to Assess Change in Disease Activity In Adult Participants With Newly Diagnosed Higher-Risk Myelodysplastic Syndrome

• Rambam Health Care Campus /ID# 222118

  Haifa, H_efa 3109601

  1 trial

  • NCT04497597A Study of Oral Upadacitinib Tablets to Assess Treatment Patterns, Achievement of Treatment Targets and Maintenance of Response in Adult Participants With Moderate to Severe Rheumatoid Arthritis

• Rambam Health Care Campus /ID# 222198

  Haifa, H_efa 3109601

  1 trial

  • NCT03821935Study to Determine the Safety, Tolerability, Pharmacokinetics and Recommended Phase 2 Dose (RP2D) of Livmoniplimab (ABBV-151) as a Single Agent and in Combination With Budigalimab (ABBV-181) in Participants With Locally Advanced or Metastatic Solid Tumors

• Rambam Health Care Campus /ID# 225586

  Haifa, H_efa 3109601

  1 trial

  • NCT04721015Study of Intravenous (IV) ABBV-637 Alone or in Combination With IV Docetaxel/Osimertinib to Assess Adverse Events and Change in Disease Activity in Adult Participants With Relapsed/Refractory (R/R) Solid Tumors

• Rambam Health Care Campus /ID# 225981

  Haifa, H_efa 3109601

  1 trial

  • NCT05578976A Study to Evaluate Change in Disease Activity of Subcutaneous (SC) Epcoritamab Combined With Intravenous and Oral Rituximab, Cyclophosphamide, Doxorubicin Hydrochloride, Vincristine, and Prednisone (R-CHOP) or R-CHOP in Adult Participants With Newly Diagnosed Diffuse Large B-Cell Lymphoma (DLBCL)

• Rambam Health Care Campus /ID# 227849

  Haifa, 3109601

  1 trial

  • NCT05409066Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Follicular Lymphoma

• Rambam Health Care Campus /ID# 229555

  Haifa, H_efa 3109601

  1 trial

  • NCT04807972Study to Evaluate Adverse Events and Change in Disease Activity When Intravenous (IV) Infusion of ABBV-927 is Administered in Combination With IV Modified FOLFIRINOX (mFFX) With or Without IV Budigalimab Compared to mFFX in Adult Participants With Untreated Pancreatic Cancer Metastasis

• Rambam Health Care Campus /ID# 230813

  Haifa, 3109601

  1 trial

  • NCT03595059A Study With ABBV-155 Alone and in Combination With Taxane Therapy in Adults With Relapsed and/or Refractory Solid Tumors

• Rambam Health Care Campus /ID# 231218

  Haifa, 3109601

  1 trial

  • NCT05029882Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 as Monotherapy and in Combination With IV Bevacizumab

• Rambam Health Care Campus /ID# 238333

  Haifa, 3109601

  1 trial

  • NCT05005403Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma and Other Solid Tumors, Receiving Intravenous Infusion of Azirkitug Alone or in Combination(s) With Budigalimab, Bevacizumab, or Telisotuzumab Adizutecan

• Rambam Health Care Campus /ID# 238732

  Haifa, 3109601

  1 trial

  • NCT05028569Study of BOTOX Injections in Prevention of Migraine in Adult Participants With Episodic Migraine

• Rambam Health Care Campus /ID# 240037

  Haifa, H_efa 3109601

  1 trial

  • NCT05206357Study of the Adverse Events and Change in Disease State of Pediatric Participants (and Young Adults Between the Ages of 18-25) With Relapsed/Refractory Aggressive Mature B-cell Neoplasms Receiving Subcutaneous (SC) Injections of Epcoritamab

• Rambam Health Care Campus /ID# 240332

  Haifa, 3109601

  1 trial

  • NCT03891446Long-term Safety and Efficacy Extension Trial of Bimatoprost SR

• Rambam Health Care Campus /ID# 244904

  Haifa, 3109601

  1 trial

  • NCT05081557A Study to Assess Real-World Use, Safety, and Effectiveness of Oral Upadacitinib in Adult and Adolescent (>=12 Years Old) Participants With Atopic Dermatitis

• Rambam Health Care Campus /ID# 249884

  Haifa, H_efa 3109601

  1 trial

  • NCT05494606An Observational Study to Assess Change in Disease Activity and Adverse Events of Upadacitinib in Adult Participants With Moderate to Severe Ulcerative Colitis (UC) in Real-World Practice

• Rambam Health Care Campus /ID# 254406

  Haifa, 3109601

  1 trial

  • NCT05889182A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy

• Rambam Health Care Campus /ID# 254608

  Haifa, 3109601

  1 trial

  • NCT06158958A Study to Assess the Safety, Pharmacokinetics, and Efficacy of Intravenous (IV) ABBV-303, as Monotherapy and in Combination With IV Infused Budigalimab (ABBV-181), in Adults With Advanced Solid Tumors

• Rambam Health Care Campus /ID# 255059

  Haifa, 3109601

  1 trial

  • NCT05599984Study to Evaluate Adverse Events, Change in Disease Activity, and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab, Cisplatin, or Carboplatin in Adult Participants With Advanced Solid Tumors

• Rambam Health Care Campus /ID# 256546

  Haifa, H_efa 3109601

  1 trial

  • NCT06068842A Study to Assess Prevalence of a Specific Protein Overexpression in Adult Participants With Non-Small Cell Lung Cancer

• Rambam Health Care Campus /ID# 256649

  Haifa, 3109601

  1 trial

  • NCT06084481Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400

• Rambam Health Care Campus /ID# 257344

  Haifa, 3109601

  1 trial

  • NCT06107413Study to Assess Adverse Events and Change in Disease Activity in Previously Treated Adult Participants Receiving Intravenous (IV) ABBV-400 With Unresectable Metastatic Colorectal Cancer in Combination With IV Fluorouracil, Folinic Acid, and Bevacizumab

• Rambam Health Care Campus /ID# 259852

  Haifa, 3109601

  1 trial

  • NCT06118411A Study To Assess Adverse Events and Effectiveness of Upadacitinib Oral Tablets in Adult and Adolescent Participants With Vitiligo

• Rambam Health Care Campus /ID# 262431

  Haifa, 3109601

  1 trial

  • NCT06236438Study to Evaluate Adverse Events, Optimal Dose, and Change in Disease Activity, With Livmoniplimab in Combination With Budigalimab Plus Chemotherapy Versus IV Infused Pembrolizumab Plus Chemotherapy in Adult Participants With Untreated Metastatic Non-Squamous Non-Small Cell Lung Cancer (NSCLC)

• Rambam Health Care Campus /ID# 270105

  Haifa, 3525408

  1 trial

  • NCT06632951Study to Evaluate Adverse Events and Change in Disease Activity When Intravenously (IV) Infused Livmoniplimab is Used in Combination With IV Infused Budigalimab in Adult Participants With Urothelial Carcinoma (UC)

• Rambam Health Care Campus /ID# 270604

  Haifa, 3109601

  1 trial

  • NCT06858813A Study to Assess Adverse Events and Change in Disease Activity of Intravenously (IV) Infused ABBV-324 in Adult Participants With Hepatocellular Cancer (HCC) or Squamous-Cell Non-Small Cell Lung Cancer (LUSC)

• Rambam Health Care Campus /ID# 278418

  Haifa, 3109601

  1 trial

  • NCT07278336A Study to Assess Adverse Events, Change in Disease Activity and How Intravenous (IV) ABBV901 Moves Through the Body Alone or in Combination With Other Anticancer Drugs in Adult Participants With Ovarian Cancer

• Rambam Health Care Campus (Site 0003)

  Haifa, 3109601

  1 trial

  • NCT06045507Safety and Pharmacokinetic Study of Oral MK-8527 QM in Participants at Low-Risk for HIV-1 Infection (MK-8527-007)

• Rambam Health Care Campus (Site 0011)

  Haifa, 3109601

  1 trial

  • NCT06686394Study of Patritumab Deruxtecan With Other Anticancer Agents in Participants With HER2 Positive Breast Cancer That Has Spread and Cannot Be Surgically Removed (MK-1022-009)

    Contact: Study Coordinator

• Rambam Health Care Campus (Site 0201)

  Haifa, 3109601

  1 trial

  • NCT06894771A Study of MK-4700 Alone or With Pembrolizumab in Participants With Advanced or Metastatic Solid Tumors (MK-4700-001)

• Rambam Health Care Campus (Site 0202)

  Haifa, 3109601

  1 trial

  • NCT06843447A Clinical Study of Raludotatug Deruxtecan in People With Ovarian Cancer (MK-5909-003).

    Contact: Study Coordinator

• Rambam Health Care Campus (Site 0304)

  Haifa, 3109601

  1 trial

  • NCT05853367Study of MK-0472 in Participants With Advanced/Metastatic Solid Tumors (MK-0472-001)

• Rambam Health Care Campus (Site 0362)

  Haifa, 3109601

  1 trial

  • NCT07419295A Clinical Trial of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) to Treat Urothelial Cancer (MK-2870-031)

    Contact: Study Coordinator

• Rambam Health Care Campus (Site 0381)

  Haifa, 31096

  1 trial

  • NCT03221426Study of Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy in Participants With Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-585/KEYNOTE-585)

• Rambam Health Care Campus (Site 0400)

  Haifa, 3109601

  1 trial

  • NCT06863272A Clinical Study of Ifinatamab Deruxtecan Based Treatment Combinations or as Monotherapy to Treat Metastatic Castrate Resistant Prostate Cancer (mCRPC) (MK-2400-01A/IDeate-Prostate02)

    Contact: Study Coordinator

• Rambam Health Care Campus (Site 0403)

  Haifa, 3109601

  1 trial

  • NCT06814145Extension Study of Sotatercept in People With Pulmonary Hypertension (MK-7962-023)

• Rambam Health Care Campus (Site 0429)

  Haifa, 3109601

  1 trial

  • NCT06456346Bomedemstat vs Hydroxyurea for Essential Thrombocythemia (MK-3543-007)

• Rambam Health Care Campus (Site 0462)

  Haifa, 3109601

  1 trial

  • NCT06925737A Clinical Study of Ifinatamab Deruxtecan (I-DXd) in People With Metastatic Prostate Cancer (MK-2400-001)

    Contact: Study Coordinator

• Rambam Health Care Campus (Site 0500)

  Haifa, 3109601

  1 trial

  • NCT07216482A Clinical Study of Enlicitide in Participants With High Cholesterol (MK-0616-037)

• Rambam Health Care Campus (Site 0602)

  Haifa, 3109601

  1 trial

  • NCT07227597A Clinical Study of Gocatamig (MK-6070) and Infinatamab Deruxtecan (MK-2400) in People With Small Cell Lung Cancer (MK-6070-003)

    Contact: Study Coordinator

• Rambam Health Care Campus (Site 0604)

  Haifa, 3109601

  1 trial

  • NCT06890884A Clinical Study of Zilovertamab Vedotin (MK-2140) Plus Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Polatuzumab Vedotin Plus R-CHP in People With Diffuse Large B-cell Lymphoma (DLBCL) (MK-2140-011/waveLINE-011)

    Contact: Study Coordinator

• Rambam Health Care Campus (Site 0700)

  Haifa, 3109601

  1 trial

  • NCT06450366A Study to Evaluate the Efficacy and Safety of Enlicitide (MK-0616, Oral PCSK9 Inhibitor) Compared With Ezetimibe or Bempedoic Acid or Ezetimibe and Bempedoic Acid in Adults With Hypercholesterolemia (MK-0616-018/CORALreef AddOn)

• Rambam Health Care Campus (Site 0801)

  Haifa, 3109601

  1 trial

  • NCT06465186A Clinical Study of Efinopegdutide in People With Compensated Cirrhosis Due to Steatohepatitis (MK-6024-017)

• Rambam Health Care Campus (Site 0803)

  Haifa, 3109601

  1 trial

  • NCT07709000A Clinical Trial of MK-1045 in People With B-cell Cancer (MK-1045-006)

    Contact: Study Coordinator

• Rambam Health Care Campus (Site 0903)

  Haifa, 3109601

  1 trial

  • NCT07570173A Clinical Trial of MK-1045 in People With B-cell Acute Lymphoblastic Leukemia (MK-1045-005)

    Contact: Study Coordinator

• Rambam Health Care Campus (Site 1004)

  Haifa, 3109601

  1 trial

  • NCT05508867A Study of Coformulated Favezelimab/Pembrolizumab (MK-4280A) Versus Physician's Choice Chemotherapy in PD-(L)1-refractory, Relapsed or Refractory Classical Hodgkin Lymphoma (MK-4280A-008)

• Rambam Health Care Campus (Site 1101)

  Haifa, 3109601

  1 trial

  • NCT06052059A Study to Evaluate Efficacy and Safety of Tulisokibart (MK-7240) in Participants With Moderately to Severely Active Ulcerative Colitis (MK-7240-001)

• Rambam Health Care Campus (Site 1201)

  Haifa, 3109601

  1 trial

  • NCT06430801A Study to Evaluate the Efficacy and Safety of Tulisokibart (MK-7240) in Participants With Moderate to Severe Crohn's Disease (MK-7240-008)

    Contact: Study Coordinator

• Rambam Health Care Campus (Site 1253)

  Haifa, 3109601

  1 trial

  • NCT06997497A Clinical Study of Calderasib (MK-1084) With Targeted Therapy and Chemotherapy in People With Colorectal Cancer (MK-1084-012/KANDLELIT-012)

    Contact: Study Coordinator

• Rambam Health Care Campus (Site 1304)

  Haifa, 3109601

  1 trial

  • NCT05877547A Clinical Study of Efinopegdutide in Participants With Precirrhotic Nonalcoholic Steatohepatitis (NASH) (MK-6024-013)

• Rambam Health Care Campus (Site 1401)

  Haifa, 3109601

  1 trial

  • NCT07060807A Clinical Study of Patritumab Deruxtecan to Treat Breast Cancer (MK-1022-016)

    Contact: Study Coordinator

• Rambam Health Care Campus (Site 1422)

  Haifa, 3109601

  1 trial

  • NCT07318558A Clinical Trial of Sac-TMT in People With Non-HRD Positive Advanced Ovarian Cancer (MK-2870-021)

    Contact: Study Coordinator

• Rambam Health Care Campus (Site 1600)

  Haifa, 3109601

  1 trial

  • NCT07489495A Clinical Study of Belzutifan (MK-6482) and Zanzalintinib in People With Renal Cell Carcinoma (RCC) (LITESPARK-034/LS-034/MK-6482-034)

    Contact: Study Coordinator

• Rambam Health Care Campus (Site 1603)

  Haifa, 3109601

  1 trial

  • NCT06623422A Study of Pembrolizumab (MK-3475) With or Without Intismeran Autogene (V940) in Participants With Non-small Cell Lung Cancer (V940-009/INTerpath-009)

    Contact: Study Coordinator

• Rambam Health Care Campus (Site 1606)

  Haifa, 3109601

  1 trial

  • NCT03615326Pembrolizumab/Placebo Plus Trastuzumab Plus Chemotherapy in Human Epidermal Growth Factor Receptor 2 Positive (HER2+) Advanced Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-811/KEYNOTE-811)

• Rambam Health Care Campus (Site 1701)

  Haifa, 3109601

  1 trial

  • NCT05612035Frespaciguat (MK-5475) INSIGNIA-PH-COPD: A Study of the Efficacy and Safety of Frespaciguat (an Inhaled sGC Stimulator) in Adults With PH-COPD

• Rambam Health Care Campus (Site 1702)

  Haifa, 3109601

  1 trial

  • NCT06008756Enlicitide Decanoate (MK-0616 Oral PCSK9 Inhibitor) Cardiovascular Outcomes Study (MK-0616-015) CORALreef Outcomes

• Rambam Health Care Campus (Site 1718)

  Haifa, 3109601

  1 trial

  • NCT06008756Enlicitide Decanoate (MK-0616 Oral PCSK9 Inhibitor) Cardiovascular Outcomes Study (MK-0616-015) CORALreef Outcomes

• Rambam Health Care Campus (Site 1739)

  Haifa, 3109601

  1 trial

  • NCT06492291Open-label Extension Study of Enlicitide Decanoate (MK-0616/Enlicitide Oral PCSK9 Inhibitor) in Adults With Hypercholesterolemia (MK-0616-019) CORALreef Extension

• Rambam Health Care Campus (Site 1742)

  Haifa, 3109601

  1 trial

  • NCT06492291Open-label Extension Study of Enlicitide Decanoate (MK-0616/Enlicitide Oral PCSK9 Inhibitor) in Adults With Hypercholesterolemia (MK-0616-019) CORALreef Extension

• Rambam Health Care Campus (Site 2002)

  Haifa, 3109601

  1 trial

  • NCT06459180A Study to Compare Sacituzumab Tirumotecan (MK-2870) Monotherapy Versus Treatment of Physician's Choice as Second-line Treatment for Participants With Recurrent or Metastatic Cervical Cancer (MK-2870-020/TroFuse-020/Gog-3101/ENGOT-cx20)

• Rambam Health Care Campus (Site 2025)

  Haifa, 3109601

  1 trial

  • NCT06952504A Study to Compare Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) Versus Pembrolizumab Alone as Treatment in Participants With Mismatch Repair Proficient Endometrial Cancer (MK-2870-033/TroFuse-033/GOG-3119/ENGOT-en29)

    Contact: Toll Free Number

• Rambam Health Care Campus (Site 2102)

  Haifa, 3109601

  1 trial

  • NCT06079879A Study of Bomedemstat (IMG-7289/MK-3543) Compared to Best Available Therapy (BAT) in Participants With Essential Thrombocythemia and an Inadequate Response or Intolerance of Hydroxyurea (MK-3543-006)

• Rambam Health Care Campus (Site 2801)

  Haifa, 3109601

  1 trial

  • NCT05947851A Study of Nemtabrutinib Plus Venetoclax vs Venetoclax + Rituximab (VR) in Second-line (2L) + Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) (MK-1026-010/BELLWAVE-010).

    Contact: Study Coordinator

• Rambam Health Care Campus (Site 3202)

  Haifa, 3109601

  1 trial

  • NCT06780137A Study to Evaluate the Safety and Efficacy of Gocatamig (MK-6070) and Ifinatamab Deruxtecan (I-DXd) in Participants With Relapsed/Refractory Extensive-Stage Small Cell Lung Cancer (MK-6070-002)

    Contact: Toll Free Number

• Rambam Health Care Campus (Site 3303)

  Haifa, 3109601

  1 trial

  • NCT07513376A Clinical Trial of Adjuvant Intismeran (V940) With or Without Pembrolizumab Coformulated With Berahyaluronidase Alfa (MK-3475A) in High-Risk Stage I Non-Small Cell Lung Cancer (V940-014)

    Contact: Study Coordinator

• Rambam Health Care Campus (Site 3674)

  Haifa, 3109601

  1 trial

  • NCT06941272A Study of Patritumab Deruxtecan in Pediatric Participants With Relapsed or Refractory Solid Tumors (MK-9999-01C/LIGHTBEAM-U01)

    Contact: Study Coordinator

• Rambam Health Care Campus (Site 3700)

  Haifa, 3109601

  1 trial

  • NCT06841354A Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Triple-Negative Breast Cancer (MK-2870-011/TroFuse-011)

    Contact: Study Coordinator

• Rambam Health Care Campus (Site 4400)

  Haifa, 3109601

  1 trial

  • NCT06966700A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)

    Contact: Study Coordinator

• Rambam Health Care Campus (Site 4501)

  Haifa, 3109601

  1 trial

  • NCT06483334A Study of Efficacy and Safety of Sacituzumab Tirumotecan (MK-2870) Plus Enfortumab Vedotin (EV) With and Without Pembrolizumab in Advanced Urothelial Carcinoma (MK-3475-04C/KEYMAKER-U04)

• Rambam Health Care Campus (Site 4674)

  Haifa, 3109601

  1 trial

  • NCT07630974A Study of Ifinatamab Deruxtecan in Pediatric Participants With Relapsed or Refractory Solid Tumors (MK-9999-01D/LIGHTBEAM-U01)

    Contact: Study Coordinator

• Rambam Health Care Campus (Site 5500)

  Haifa, 3109601

  1 trial

  • NCT07049926Substudy 03C: A Study of Combination Therapies in Participants With Renal Cell Carcinoma With Recurrent Disease During or After Anti-PD-(L)1 Therapy (MK-3475-03C/KEYMAKER-U03)

    Contact: Study Coordinator

• Rambam Health Care Campus (Site 5501)

  Haifa, 3109601

  1 trial

  • NCT07232602KEYMAKER-U04 Substudy 04D: A Clinical Study of New Treatments Given With Enfortumab Vedotin and Pembrolizumab in People With Urothelial Cancer (MK-3475-04D/KEYMAKER-U04)

    Contact: Study Coordinator

• Rambam Health Care Campus,Substudy-01

  Haifa, 3525408

  1 trial

  • NCT05633667Study of Novel Treatment Combinations in Patients With Lung Cancer

• Rambam Health Care Campus,Substudy-02

  Haifa, 3525408

  1 trial

  • NCT05633667Study of Novel Treatment Combinations in Patients With Lung Cancer

• Rambam Health Care Campus,Substudy-03

  Haifa, 3525408

  1 trial

  • NCT05633667Study of Novel Treatment Combinations in Patients With Lung Cancer

• Rambam Health Care Campus, Technion - Israel Institute of Technology

  Haifa, 3109601

  1 trial

  • NCT07919015Real-world Study of Nerandomilast in Patients With Idiopathic Pulmonary Fibrosis and Progressive Pulmonary Fibrosis

    Contact: Yaniv Dotan, MD, PhD

• Rambam Health Care Campus, Urology Department

  Haifa

  1 trial

  • NCT07728474LCS103 Herbal Formula for Secondary Prevention of Non-Muscle Invasive Urothelial Carcinoma of the Bladder

    Contact: Etan Eigner, Dr.

• Rambam Hospital

  Haifa, 3109601

  1 trial

  • NCT05199337Phase 1/2 Study of ZN-d5 for the Treatment of Relapsed or Refractory Light Chain (AL) Amyloidosis